Geographic disparities in trends of thyroid cancer incidence and mortality from 1990 to 2019 and a projection to 2030 across income-classified countries and territories

Chenran Wang, Zheng Wu, Lin Lei, Xuesi Dong, Wei Cao, Zilin Luo, Yadi Zheng, Fei Wang, Yongjie Xu, Liang Zhao, Jufang Shi, Jiansong Ren, Jibin Li, Yawei Zhang, Wanqing Chen, Ni LiJournal of Global Health 2023 · DOI

Abstract

Opposite patterns in incidence and mortality of thyroid cancer (TC) raise concerns about overdiagnosis, particularly in upper-middle-income and high-income countries. Discrepancies in the distribution of health service accessibility, including diagnostic techniques and therapeutic care, should be addressed by narrowing health inequalities in the TC burden across countries.

Introduction: The Thyroid Cancer Paradox

Recent research published in the Journal of Global Health highlights a striking epidemiological phenomenon known as the "thyroid cancer paradox." While the global incidence of thyroid cancer has surged over the past three decades, mortality rates have remained remarkably stable or have even declined in many regions. This divergence suggests that while we are detecting more cases than ever before, many of these diagnoses may involve indolent tumors that pose little threat to patient life—a classic sign of medical overdiagnosis.

Methodology: Analyzing the Global Burden

Researchers conducted a secondary analysis of the 2019 Global Burden of Disease (GBD) study, covering 201 countries and territories. To understand the underlying drivers of these trends, the team utilized Age-Period-Cohort (APC) analysis to separate the effects of biological aging from technological shifts (such as the introduction of high-resolution ultrasound) and generational risk factors. Furthermore, a Bayesian APC model was employed to project incidence and mortality rates through 2030, while correlation analyses compared these trends against the Universal Health Coverage (UHC) index and health worker density.

The Overdiagnosis Signal: Rising Incidence in Wealthy Nations

Between 1990 and 2019, the absolute number of new TC cases globally rose by 167%. This growth is most pronounced in high-income countries (HICs), which accounted for over a third of global cases in 2019 despite representing a smaller fraction of the world population.

Percentage change in age-standardized incidence rates (ASIR) of thyroid cancer by country income group (1990–2019).

The study identifies a clear "overdiagnosis signal" in HICs, where advanced imaging techniques like ultrasound and CT scans detect tiny microcarcinomas that would have previously gone unnoticed. South Korea serves as a primary cautionary tale; a national screening program led to a massive surge in diagnoses (with some estimates exceeding 500% growth) without a corresponding change in mortality. This suggests that many patients are undergoing invasive surgeries and lifelong hormone therapy for non-lethal conditions.

The Mortality Gap: Vulnerability in Developing Regions

While HICs grapple with over-detection, lower-middle-income countries (LMICs) face a different crisis. Unlike wealthier nations where mortality is declining, many LMICs have seen an increase in age-standardized mortality rates (ASMR). This indicates that in these regions, the rise in cases likely includes more advanced, lethal cancers that are not being caught or treated effectively due to limited healthcare infrastructure.

Percentage change in age-standardized mortality rates (ASMR) of thyroid cancer by country income group (1990–2019).

Correlation data shows that while stronger health systems (higher UHC index and doctor density) are better at finding cancer, they are also significantly better at treating dangerous cases, leading to lower mortality. Conversely, regions with lower health service accessibility suffer from a lack of both early detection for aggressive tumors and adequate therapeutic care.

Future Projections: The 2030 Outlook

The study’s Bayesian model predicts that the global TC burden will continue to grow. By 2030, total cases are projected to increase by another 44.1%. While age-standardized mortality rates are expected to continue their general downward trend globally, the absolute number of deaths will likely rise due to population growth and aging, particularly in lower-income regions.

Conclusion and Recommendations

The researchers conclude that a one-size-fits-all approach to thyroid cancer is insufficient. High-income countries must refine clinical guidelines to scale back unnecessary screening and avoid the harms of overdiagnosis. Meanwhile, international health efforts should prioritize improving access to basic diagnostic and therapeutic services in lower-income regions to curb rising mortality and narrow the global health inequality gap.

Summary updated

Abstract

Opposite patterns in incidence and mortality of TC raise concerns about overdiagnosis, particularly in upper-middle-income and high-income countries. Discrepancies in the distribution of health service accessibility, including diagnostic techniques and therapeutic care, should be addressed by narrowing health inequalities in the TC burden across countries.
BibTeX
@article{wang2023geographic,
  author = {Chenran Wang and Zheng Wu and Lin Lei and Xuesi Dong and Wei Cao and Zilin Luo and Yadi Zheng and Fei Wang and Yongjie Xu and Liang Zhao and Jufang Shi and Jiansong Ren and Jibin Li and Yawei Zhang and Wanqing Chen and Ni Li},
  title = {{Geographic disparities in trends of thyroid cancer incidence and mortality from 1990 to 2019 and a projection to 2030 across income-classified countries and territories}},
  journal = {Journal of Global Health},
  year = {2023},
  doi = {10.7189/jogh.13.04108},
}
Figure